永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

交易中 05-09 09:33:00

3.690

+0.000

0.00%

最高3.690	最低3.690	成交量0.00
今开3.690	昨收3.690	日振幅0.00%
总市值18.99亿	流通市值18.99亿	总股本5.15亿
成交额0.00	换手率0.00%	流通股本5.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.69,"timestamp":1746752400868,"preClose":3.69,"halted":0,"volume":0,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.38973252780432466,"marketStatus":"交易中","change":0,"latestTime":"05-09 09:33:00","open":3.69,"high":3.69,"low":3.69,"amount":0,"amplitude":0,"askPrice":3.9,"askSize":6000,"bidPrice":3.55,"bidSize":59000,"shortable":0,"etf":0,"ttmEps":-0.38973252780432466,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1746763200000},"marketStatusCode":2,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.69,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/tweets","defaultTab":"tweets","newsList":[{"id":"2534270154","title":"英硅智能更新招股书 冲刺港交所主板AI创新药首股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534270154","media":"观点地产网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534270154?lang=zh_cn&edition=full","pubTime":"2025-05-08 23:28","pubTimestamp":1746718080,"startTime":"0","endTime":"0","summary":"观点网讯：5月8日，英硅智能更新招股书，再度冲刺港交所主板AI创新药第一股。根据弗若斯特沙利文的资料，英硅智能是一家全球领先的AI驱动生物科技公司，其一项处于II期临床阶段的资产是全球同领域公司中进展最快的项目。另据招股书披露，英硅智能的业务包括三大板块：药物发现及管线开发、软件解决方案及与非制药领域相关的其他发现。于业绩记录期，公司尚无自研管线到达商业化阶段，收入主要来自于其他管线药物开发业务。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2025-05-08/doc-inevwuen4911456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","159992","06978"],"gpt_icon":0},{"id":"2533390448","title":"健康元：目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2533390448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533390448?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:27","pubTimestamp":1746700038,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元05月08日在投资者关系平台上答复投资者关心的问题。我们理解广大投资者对公司创新药业务的重视和期待，目前公司已上市的创新药占整体业绩比例较小，因此暂未单独详细披露。未来，相信公司创新药陆续上市后，在创新药产品进入快速增长期或成为营收主力时，我们将考虑根据市场需求和监管政策，优化信息披露内容，以便投资者更好地理解创新药对公司业绩的贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK1574","BK0028","06978","BK0046","BK0114","BK0188","600380","BK1161","BK0077"],"gpt_icon":0},{"id":"2533190458","title":"健康元：目前在吸入制剂板块中仅有妥布霉素吸入溶液这一创新药品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2533190458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533190458?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:21","pubTimestamp":1746699681,"startTime":"0","endTime":"0","summary":"证券之星消息，健康元05月08日在投资者关系平台上答复投资者关心的问题。目前，在公司的吸入制剂板块中，仅有妥布霉素吸入溶液这一创新药品种。未来，随着公司一系列创新药产品陆续获批上市，当创新药产品进入快速增长期，或者成为公司营收的主要贡献力量时，我们会充分考虑市场的实际需求以及监管政策的相关要求，对信息披露内容进行优化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","600380","BK0188","BK0077","BK0239","06978","BK0046","BK0114","BK1161","BK0028","159992"],"gpt_icon":0},{"id":"2533904310","title":"健康元：仿制药业务受集采政策影响，创新药管线处于研发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2533904310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533904310?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:21","pubTimestamp":1746699680,"startTime":"0","endTime":"0","summary":"一方面，仿制药业务由于受到集采等政策因素的持续影响，面临较大压力。另一方面，公司的创新药管线目前主要处于研发阶段，从研发到成功上市并为公司贡献业绩，确实还需要一定的时间周期。后续，我们也会更多地披露创新药研发和上市的进展情况，希望您能给予我们更多的耐心和支持，与公司一同见证创新转型的成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800027916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0046","600380","BK0114","BK0077","BK0188","BK0239","06978","159992","BK1574","BK0028"],"gpt_icon":0},{"id":"2533909490","title":"总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2533909490","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533909490?lang=zh_cn&edition=full","pubTime":"2025-05-08 18:13","pubTimestamp":1746699211,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0109394709.USD","LU2417539215.USD","BK4568","06978","BK4588","LU2456880835.USD","LU1829250122.USD","BK1161","BK4585","AZN","BK4007","LU2236285917.USD","LU0320765992.SGD","LU2462157665.USD","159992","LU0889565916.HKD","BK1574"],"gpt_icon":0},{"id":"2533903671","title":"永泰生物-B05月08日主力净流出28.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2533903671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533903671?lang=zh_cn&edition=full","pubTime":"2025-05-08 16:15","pubTimestamp":1746692137,"startTime":"0","endTime":"0","summary":"05月08日, 永泰生物-B股价跌1.86%，报收3.69元，成交金额117.7万元，换手率0.06%，振幅10.64%，量比2.66。永泰生物-B今日主力资金净流出28.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌4.15%，主力资金累计净流出28.8万元；近20日主力资金累计净流出60.5万元，其中净流出天数为2日。该股主力净额占比0.02%，港股市场排名2428/2646。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173626a6d77288&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508173626a6d77288&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2533916440","title":"永泰生物-B盘中异动 大幅上涨5.05%报3.950港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533916440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533916440?lang=zh_cn&edition=full","pubTime":"2025-05-08 09:36","pubTimestamp":1746668213,"startTime":"0","endTime":"0","summary":"2025年05月08日早盘09时36分，永泰生物-B股票出现异动，股价急速拉升5.05%。截至发稿，该股报3.950港元/股，成交量2000股，换手率0.00%，振幅0.00%。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.04%。消息层面，截至09时36分，《永泰生物-B：2024年亏损1.87亿元》资讯为影响永泰生物-B的重要信息。该信息摘要如下：中证智能财讯永泰生物-B4月29日披露2024年度报告。以4月29日收盘价计算，永泰生物-B目前市净率约-138.34倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050809365497528b3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050809365497528b3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2533622568","title":"涉及减肥药？股价盘中多次触及涨停 常山药业回应：艾本那肽无最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533622568","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533622568?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:16","pubTimestamp":1746602164,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0070","159992","BK1161","BK0239","300255","BK0172","06978","BK1574"],"gpt_icon":0},{"id":"2533462501","title":"创新药概念持续调整 百济神州跌7.31% 机构指医药板块中最值得关注的仍是创新药赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2533462501","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533462501?lang=zh_cn&edition=full","pubTime":"2025-05-07 14:03","pubTimestamp":1746597782,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念持续调整，加科思 跌13.95%，百济神州跌7.31%，君实生物跌6.75%，荣昌生物跌6.6%，药明生物跌6.24%。国金证券研报指，医药板块中最值得关注的仍将是创新药赛道，该行认为对创新医药投资机会的把握将是贯穿2025年全年医药投资的主线，在当前时点重点看好创新药出海龙头和仿创结合龙头，同时积极关注会议数据发布和海外BD商务合作进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050714034194eedfd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1588","09939","LU2328871848.SGD","BK1500","LU0307460666.USD","BK1574","LU0588546209.SGD","BK1583","BK1161","LU1969619763.USD","06978","BK1515"],"gpt_icon":0},{"id":"2533623745","title":"A股创新药概念午后持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533623745?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2148510915.USD","BK0196","159992","06978","BK1583","399300","LU1969619763.USD","BK4139","LU0307460666.USD","BK0239","688382","BK1574","688235","BK0028","002294","LU0588546209.SGD","LU2328871848.SGD","300723","159982","09995","BK0188","BK1500","BK1588","LU1064131003.USD","06160","BK0183","BK1161","ONC","LU1064130708.USD","688192","688331","BK0187"],"gpt_icon":0},{"id":"2533253366","title":"【创新药概念持续调整 百济神州跌近9%】午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533253366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533253366?lang=zh_cn&edition=full","pubTime":"2025-05-07 13:54","pubTimestamp":1746597245,"startTime":"0","endTime":"0","summary":"午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07135450187475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064130708.USD","LU0588546209.SGD","ONC","BK0183","BK1574","LU1969619763.USD","BK1500","BK1161","BK0187","LU2148510915.USD","09995","159992","002294","LU0307460666.USD","BK4139","688382","688331","06160","BK0028","LU1064131003.USD","688235","06978","688192","LU2328871848.SGD","300723","BK1588","BK0188","BK1583","BK0239","BK0196"],"gpt_icon":0},{"id":"2533213691","title":"昌平区一季度GDP同比增长7.9%！民企助力跑赢全市增速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533213691","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533213691?lang=zh_cn&edition=full","pubTime":"2025-05-07 07:03","pubTimestamp":1746572580,"startTime":"0","endTime":"0","summary":"在民营企业的活力助推下，昌平区实现经济“开门红”，一季度地区生产总值同比增长7.9%，跑赢全市增速。创新安全电池接到储能大单先进能源是昌平区的三大主导产业之一，这一领域也成为民营企业创新热点。悉心培育下，民营经济正成为昌平区经济发展、科技创新的重要动力。2024年昌平区规模以上民营企业达2109家，占全区规模以上企业比重为79.8%，实现收入3494.3亿元，同比增长12.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-07/doc-inevssqf3893232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4213","06978","BK1161","GDP","BK1574","09969"],"gpt_icon":0},{"id":"2533850000","title":"重磅!远大医药(00512)全球创新药STC3141中国II期临床数据亮剑，脓毒症治疗迎来突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533850000","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533850000?lang=zh_cn&edition=full","pubTime":"2025-05-06 18:28","pubTimestamp":1746527318,"startTime":"0","endTime":"0","summary":"智通财经APP讯，近日，港股科技创新型国际化医药企业远大医药 传来一则重磅消息，公司自主研发的全球创新药物STC3141在中国开展的用于治疗脓毒症的II期临床研究成功达到临床终点，试验结果证实了STC3141在脓毒症治疗中的有效性和安全性，该临床研究进度处于全球脓毒症研究领域前列。后续，远大医药将积极与药监局展开深度沟通，申请突破性治疗药物资格，让STC3141尽早惠及广大脓毒症患者，填补临床空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","159992","BK1161","00512","BK1191","BK1574"],"gpt_icon":0},{"id":"2533506642","title":"消费医疗的春天还早，但有人还是吃到红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506642","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533506642?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:37","pubTimestamp":1746520624,"startTime":"0","endTime":"0","summary":"2024年，医疗行业继续在复杂的市场变化中找寻自身路径。一方面，大健康的热潮一度让市场认为消费医疗将成为趋势新红利。但纵览相关赛道的上市公司年报，这种红利的兑现远未到来。另一方面，“卷”仍是国内医疗行业避开不了的关键词。最后，当下的医疗行业是否没有细分赛道处于红利期，答案是否定的。疫苗行业的高光时刻，终结于疫情结束。血液制品的赛道，各家都实现增长，但增速各有不同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/256521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2488822045.USD","BK1583","BK1574","LU2328871848.SGD","01801","06978","BK1161","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2533463235","title":"医药生物行业周报：业绩修复周期开启，双主线聚焦“创新药+AI医疗”","url":"https://stock-news.laohu8.com/highlight/detail?id=2533463235","media":"信达证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533463235?lang=zh_cn&edition=full","pubTime":"2025-05-06 16:08","pubTimestamp":1746518928,"startTime":"0","endTime":"0","summary":"本期内容提要:市场表现：上周医药生物板块收益率为0.49%，板块相对沪深300收益率为0.93%，在31个一级子行业指数中涨跌幅排名第9。我们认为随着医疗整顿负面影响逐步消化，院内市场有望逐步恢复，叠加院外消费医疗需求复苏，25Q2医药板块有望整体迎来业绩修复，建议重点关注复苏逻辑及经营改善逻辑的板块和个股，此外，随着降息降准预期提升，创新药+AI医疗主题仍有望成为下一阶段的进攻方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506161143975067aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","LU0181495838.USD","LU0823426480.USD","LU0140636845.USD","LU0359202008.SGD","LU0516422952.EUR","LU0856984785.SGD","LU0979878070.USD","LU0417516738.SGD","LU1794554557.SGD","LU0823426308.USD","LU1242518857.USD","LU0516423174.USD","LU0359201612.USD","LU1880383366.USD","LU0516423091.SGD","LU0708995583.HKD","SG9999002562.SGD","LU0307460666.USD","BK1589","LU0043850808.USD","LU0326950275.SGD","BK1574","IE00B0JY6N72.USD","LU0588546209.SGD","LU0819121731.USD","LU0051755006.USD","BK1141","LU0320764599.SGD","LU0327786744.USD","LU2039709279.SGD","LU0456827905.SGD","09926","BK1610","LU0456846285.SGD","LU1720050803.USD","LU0348735423.USD","02269","LU0039217434.USD","LU0348825331.USD","LU0417516902.SGD","LU0052750758.USD","LU1688375341.USD","01801","LU1242518931.SGD","BK1161","LU0516422366.SGD","06978","BK1521","LU0572944931.SGD","SG9999002463.SGD","LU0516422440.USD"],"gpt_icon":0},{"id":"2533509697","title":"翰森制药2024年溢利增长33% 创新药方面为核心支柱","url":"https://stock-news.laohu8.com/highlight/detail?id=2533509697","media":"GPLP犀牛财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533509697?lang=zh_cn&edition=full","pubTime":"2025-05-06 15:58","pubTimestamp":1746518308,"startTime":"0","endTime":"0","summary":"4月28日，翰森制药发布年报，2024年录得收入122.61亿元，同比增长约21.3%；录得年内溢利约43.72亿元，同比增长约33.4%；基本每股盈利为0.74元/股，业绩增长主要得益于创新药及合作产品收入增加。2024年，翰森制药的创新药与合作产品销售收入为94.77亿元，占总收入比例提升至77.3%，成为业绩增长核心动力。2024年，翰森制药研发开支为27.02亿元，同比增长约28.8%，目前正在进行的创新药临床试验超60项，分属40个候选创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506155847975064cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506155847975064cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","06978","03692","BK1191","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2533113566","title":"高瓴资本超级重仓！绝对是最被低估的创新药龙头，甚至没有之一！","url":"https://stock-news.laohu8.com/highlight/detail?id=2533113566","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533113566?lang=zh_cn&edition=full","pubTime":"2025-05-05 20:58","pubTimestamp":1746449903,"startTime":"0","endTime":"0","summary":"在药明生物的规划中，未来最大的收入来源会变成药品的销售分成，药明如此，目前看来金斯瑞也有这个潜力。按照金斯瑞投资者交流的说法，蓬勃生物有超过30个新分子开发项目，包括多种分子类型，覆盖多个高价值领域，截至目前，已有16个对外授权项目组，其中两项已进入临床阶段，合作方式包括付费服务、共同开发、生产买断以及对外授权等形式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506005829a6d4062d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506005829a6d4062d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348805143.USD","LU0345776255.USD","HK0000320264.USD","LU0488056044.USD","BK1502","LU0791590937.USD","LU1808992512.USD","IE00BGV7N243.SGD","LU0051755006.USD","LU0084288322.USD","LU0314109678.HKD","LU0384037296.USD","LU1328277881.USD","LU2039709279.SGD","BK1142","LU0164865239.USD","LU0588545490.SGD","89618","LU0163747925.USD","LU1282649810.SGD","LU0572944931.SGD","LU0345775950.USD","LU1770036033.HKD","LU0320764599.SGD","LU0370786039.SGD","LU0140636845.USD","LU0871576103.HKD","LU1044875133.USD","LU0499858602.USD","01548","IE0032431581.USD","SG9999002828.SGD","LU0431992006.USD","06978","LU0456827905.SGD","LU0456842615.SGD","BK1574","LU0315178854.USD","LU0228367735.SGD","BK1575","LU0048580855.USD","LU0791591158.USD","BK1249","LU1481107354.HKD","LU1720050803.USD","HK0000306685.HKD","LU0327786744.USD","LU0307460666.USD"],"gpt_icon":1},{"id":"2532868288","title":"叮当健康：旗下药房上架礼来阿尔茨海默病创新药记能达®","url":"https://stock-news.laohu8.com/highlight/detail?id=2532868288","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532868288?lang=zh_cn&edition=full","pubTime":"2025-05-02 11:31","pubTimestamp":1746156714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["06978","LU0471298777.SGD","LU2552382132.HKD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0094547139.USD","LU0106261372.USD","SGXZ57979304.SGD","09886","LU0238689110.USD","LU1989771016.USD","LU1064131342.USD","LU0943347566.SGD","LU1623119135.USD","LU2552382215.SGD","SG9999014914.USD","SG9999015945.SGD","LU2237443382.USD","LU0820561818.USD","159992","LU2471134523.USD","IE00BK4W5M84.HKD","SG9999001176.SGD","LU2491049909.HKD","LU0096364046.USD","LU2602419157.SGD","IE0002141913.USD","MCI","BK4599","LU0354030511.USD","LU0689472784.USD","LU2471134796.USD","LU0203201768.USD","LU2237443465.HKD","LU0708995401.HKD","LU0203202063.USD","LU0006306889.USD","SGXZ99366536.SGD","LU1057294990.SGD","LU0058720904.USD","LU0256863902.USD","SG9999015978.USD","LLY","LU0354030438.USD","BK4007","LU0640476718.USD","LU1280957306.USD","LU1035775433.USD","LU2360106947.USD","LU2491050071.SGD"],"gpt_icon":0},{"id":"2531702177","title":"阳光诺和：公司将要收购的朗研生命将采取仿制药与创新药协同发展的模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702177","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531702177?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:52","pubTimestamp":1746003148,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司将要收购的标的朗研投资目前是以生产仿制药为主，将来是像恒瑞一样向生产创新药为主转型还是继续以生产仿制药为主？阳光诺和回复：尊敬的投资者，您好！公司将要收购的朗研生命将采取仿制药与创新药协同发展的模式。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0216","688621","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2531706228","title":"永泰生物-B盘中异动 临近收盘股价大涨5.96%报4.090港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531706228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531706228?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:59","pubTimestamp":1745999985,"startTime":"0","endTime":"0","summary":"2025年04月30日临近收盘15时59分，永泰生物-B股票出现波动，股价大幅拉升5.96%。截至发稿，该股报4.090港元/股，成交量4.9万股，换手率0.01%，振幅5.44%。资金方面，该股资金流入13.433万港元，流出2.33万港元。永泰生物-B股票所在的生物技术行业中，整体涨幅为1.27%。其相关个股中，康希诺生物、乐普生物-B、帝王国际投资涨幅较大，振幅较大的相关个股有康希诺生物、乐普生物-B、绿竹生物-B，振幅分别为13.32%、12.39%、10.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430155945974b4625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430155945974b4625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0934},{"period":"1month","weight":0.0696},{"period":"3month","weight":0.6043},{"period":"6month","weight":1.05},{"period":"1year","weight":0.1677},{"period":"ytd","weight":0.6043}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.1316},{"period":"3month","weight":0.0777},{"period":"6month","weight":0.0988},{"period":"1year","weight":0.2436},{"period":"ytd","weight":0.1354}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.004443},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}